Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06747871 · ClinicalTrials.gov registry record · NA

Opioids, Low Nicotine Cigarettes, and Chronic Pain

A NA study of Chronic Pain and Tobacco Use, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06747871 is a NA study of Chronic Pain and Tobacco Use that is actively recruiting participants, run by Duke University. The registered enrollment target is 60 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06747871, a NA study of Chronic Pain and Tobacco Use, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphine treatment (OBBT).

Interventions

  • BEHAVIORAL Very Low Nicotine Cigarettes (VLNC)
  • BEHAVIORAL Normal Nicotine Cigarettes (NNC)

Study Locations (1)

North Carolina

  • North Pavilion - Durham

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-04-15
Est. Completion 2027-07-30
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT06747871

The ClinicalTrials.gov registry entry for NCT06747871 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (92% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Very Low Nicotine Cigarettes (VLNC) is the first listed.

NCT06747871 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06747871 about?

NCT06747871 is a clinical study titled "Opioids, Low Nicotine Cigarettes, and Chronic Pain". The purpose of this study is to evaluate the effects of switching to very low nicotine content (VLNC) cigarettes versus normal nicotine content (NNC) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphin...

What is the current status of trial NCT06747871?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-04-15. Estimated completion is 2027-07-30.

What conditions does trial NCT06747871 study?

This clinical trial studies the following conditions: Chronic Pain, Tobacco Use, Opioid Substitution Treatment.

What interventions are being tested in trial NCT06747871?

The interventions under investigation include: Very Low Nicotine Cigarettes (VLNC) (BEHAVIORAL), Normal Nicotine Cigarettes (NNC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06747871?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06747871 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.